Establishment Labs Holdings Inc. ESTA

What this company does

Establishment Labs produces silicone gel-filled breast implants, branded as Motiva Implants, which form the centerpiece of its medical technology platform. Since launching Motiva Implants in October 2010, the majority of its revenue has been generated from sales of Motiva Implants. Its products are commercially available in over 100 countries through exclusive distributors, except in the United States, Brazil, Argentina and several European countries, where it sells through its direct sales force. The company manufactures its products in ISO-13485-certified manufacturing facilities located in the Coyol Free Zone office park in Alajuela, Costa Rica, operating two facilities there: the original facility, opened at the end of 2016, with capacity to produce over 400,000 implants a year, and the Sulàyöm Innovation Campus, finalized in June 2024, which increased its manufacturing capacity by approximately 730,000 units per year. As of December 31, 2025, its sales organization included 278 employees and contractors. As of December 31, 2025, the company had 1,004 employees. Its portfolio includes five product families of Motiva Implants: Round and Ergonomix Round, Ergonomix Oval, Anatomical TrueFixation, Ergonomix2 Round and Ergonomix2 Diamond, and Flora Tissue Expander. Establishment Labs initially incorporated in Costa Rica in 2004 and subsequently reorganized in 2013 under a parent holding company in the British Virgin Islands.

Written from the business description in ESTABLISHMENT LABS HOLDINGS INC.'s annual report to the U.S. Securities and Exchange Commission, filed 27 February 2026. Every sentence was checked against that document before publication.